1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

  • February 2014
  • 58 pages
  • GlobalData
Report ID: 2081700

Summary

Table of Contents

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Brexpiprazole is a D2-preferring D3/D2 receptor partial agonist in development by Otsuka. As a partial agonist, like cariprazine (a D3 partial agonist), brexpiprazole helps to stabilize dopaminergic tone in periods of hyper- or hypoactivity. Brexpiprazole has broad activity across multiple monoamine systems, including 5-HT1A partial agonism and antagonism at 5-HT2A a1 receptors, which may lessen the occurrence of EPS, although it acts on D2 receptors (Stahl, 2013). Brexpiprazole is also an antagonist at 5-HT7 receptors, which may make it useful as an antidepressant. Given its diverse activity profile, it is also being investigated in dementia, ADHD, PTSD, sleep disorders, and MDD. As its name suggests, brexpiprazole may be considered as a successor to Otsuka’s Abilify (aripiprazole), which faces patent expiration in April 2015.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Brexpiprazole including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Brexpiprazole for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Brexpiprazole performance
- Obtain sales forecast for Brexpiprazole from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Antipsychotic Drugs Market By Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify), By Application (Schizophrenia, Bipolar disorder, Dementia, Unipolar Depression) And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • February 2017
  • by Grand View Research

The global antipsychotic drugs market is expected to reach USD 14.4 billion by 2025, according to a new report by Grand View Research, Inc. The continuous development of better next-generation products ...

Global Antipsychotic Drugs Market Analysis & Trends - Industry Forecast to 2025

  • $ 4200
  • Industry report
  • April 2017
  • by Accuray Research LLP

The Global Antipsychotic Drugs Market is poised to grow at a CAGR of around 2.5% over the next decade to reach approximately $14.91 billion by 2025. This industry report analyzes the market estimates and ...

Mental Illness Drugs Markets in China

  • $ 4000
  • Industry report
  • May 2017
  • by Asia Market Information & Development Company

China’s demand for Mental Illness Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...


Download Unlimited Documents from Trusted Public Sources

Antimalarials and Antipsychotic Market in the US

  • June 2017
    7 pages
  • Antimalarials  

    Antipsychotic  

    Dermatological ...  

  • United States  

View report >

Antipsychotic Market and Psychotic Disorder Statistics in Europe

  • May 2017
    2 pages
  • Antipsychotic  

    Therapy  

    Psychotic Disor...  

  • Europe  

    World  

    Hungary  

View report >

Opioid Market

  • May 2017
    24 pages
  • Opioid  

View report >

Related Market Segments :

Antipsychotic
Psychotic Disorder

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.